2024 Microbiome Market Trends Report: Competitive Environment Analysis, Digital Platform and Marketing Strategies, and AI Adoption in the Industry [Yahoo! Finance]
Seres Therapeutics, Inc. (MCRB)
Last seres therapeutics, inc. earnings: 11/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.serestherapeutics.com
Company Research
Source: Yahoo! Finance
In the microbiome therapeutics market, some microbiome drugs have succeeded in commercialization. The microbiome market is growing not only in therapeutics but also in food-related markets. For example, consumers recognize probiotics as good for the body, and the food-related market is expected to form the largest share of microbiome applications due to the growing focus on health. BIOMICTRA, developed by BiomeBank, was approved by the Australian Department of Medicines and Medicines as a microbiome drug for recurrent C. difficile infections in 2022. In the U.S., Seres Therapeutics' SER-109 and Rebiotix's RBX-2660 received U.S. FDA approval and entered the market successfully in 2023. On the other hand, Seres Therapeutics and Rebiotix have also succeeded in commercializing microbiome therapeutics but have recently laid off their products, and the burden of their development costs is also an issue.In addition, due to the growing awareness of gender neutrality, the number of divers
Show less
Read more
Impact Snapshot
Event Time:
MCRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCRB alerts
High impacting Seres Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MCRB
News
- Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $10.00 price target on the stock.MarketBeat
- Seres Therapeutics to Participate in Cantor 2024 Global Healthcare ConferenceGlobeNewswire
- Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) [Yahoo! Finance]Yahoo! Finance
- Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)GlobeNewswire
- Emerging microbiome market – unlocking new frontiers [Yahoo! Finance]Yahoo! Finance
MCRB
Earnings
- 8/13/24 - Beat
MCRB
Sec Filings
- 9/12/24 - Form DEFA14A
- 9/12/24 - Form 8-K
- 8/26/24 - Form DEFM14A
- MCRB's page on the SEC website